Received Jul 1, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 1 | W023682 | — |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 1 | U033212 | — |
HCP states a patient has had interrupted schedules for VAQTA and RECOMBIVAX HB vaccination series. HCP states the patient received their first dose of VAQTA in 2022 ( exact date unknown) and has not received an additional dose and is now aged 18 year; Caller verified no side effects or symptoms reported.; This Spontaneous report was received from Nurse and referred to a/an 18-years-old ( Race Unknown ) ( Ethnicity Unknown) Female Adult patient. The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medications were not reported. In 2022, the patient started therapy with Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 (0.50 mL) (total) (Batch/Lot Number: U033212) (Expiration date: 07-Nov-2022). In 2023, the patient started therapy with Hepatitis B Vaccine (Recombinant), 5 mcg/0.5mL Suspension for injection 64457246:4093 (0.50 mL) (total) (Batch/Lot Number: W023682) . The patient started therapy with Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 for the treatment of Prophylaxis, The patient started therapy with Hepatitis B Vaccine (Recombinant), 5 mcg/0.5mL Suspension for injection 64457246:4093 for the treatment of Prophylaxis, On an unknown date, the patient experienced Caller verified no side effects or symptoms reported. (No adverse event). On an unknown date, the patient experienced HCP states a patient has had interrupted schedules for VAQTA and RECOMBIVAX HB vaccination series. HCP states the patient received their first dose of VAQTA in 2022 ( exact date unknown) and has not received an additional dose and is now aged 18 year (Inappropriate schedule of product administration). The Outcome of Inappropriate schedule of product administration was not provided. The Outcome of No adverse event was not provided. The action taken with Hepatitis B Vaccine (Recombinant), 5 mcg/0.5mL Suspension for injection 64457246:4093 regarding Inappropriate schedule of product administration was Not applicable with Not Applicable dechallenge and rechallenge results. The action taken with Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 regarding Inappropriate schedule of product administration was Not applicable with Not Applicable dechallenge and rechallenge results. Case Assessments: Hepatitis B Vaccine (Recombinant), 5 mcg/0.5mL Suspension for injection 64457246:4093 regarding No adverse event with Not Applicable dechallenge and rechallenge results. Case Assessments: Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 regarding No adverse event with Not Applicable dechallenge and rechallenge results. The Nurse considered the event No adverse event (,) to be not assessed to Hepatitis B Vaccine (Recombinant), 5 mcg/0.5mL Suspension for injection 64457246:4093, the event Inappropriate schedule of product administration (,) to be not assessed to Hepatitis B Vaccine (Recombinant), 5 mcg/0.5mL Suspension for injection 64457246:4093, the event No adverse event (,) to be not assessed to Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095, and the event Inappropriate schedule of product administration (,) to be not assessed to Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 The Nurse considered the event No adverse event to be non-serious and the event Inappropriate schedule of product administration to be non-serious